Intervention

Atezolizumab and Recombinant Human Hyaluronidase

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting1

Common conditions11

Lead sponsors shown2

Clinical trials

2 shown

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialNCT07388524 · 2027-03-02

RECRUITING

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung CancerNCT05340309 · 2022-12-07

ACTIVE_NOT_RECRUITING

Common conditions

Lung Non-Small Cell Carcinoma2 Stage II Lung Cancer AJCC v81 Stage IIA Lung Cancer AJCC v81 Stage IIB Lung Cancer AJCC v81 Stage III Lung Cancer AJCC v81 Stage IIIA Lung Cancer AJCC v81 Stage IIIB Lung Cancer AJCC v81 Stage IIIC Lung Cancer AJCC v81 Stage IV Lung Cancer AJCC v81 Stage IVA Lung Cancer AJCC v81 Stage IVB Lung Cancer AJCC v81

Leading sponsors

National Cancer Institute (NCI) 1 University of Southern California 1

Trial status mix

ACTIVE_NOT_RECRUITING1

RECRUITING1

Phase mix

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.